Nanocarriers of nanotechnology in retinal diseases

Saudi Journal of Ophthalmology

Volumn 28, Issue 4, 2014, Pages 304-309

  Al Halafi, Ali M ^a  

^a SECURITY FORCES HOSPITAL   (Saudi Arabia)

Author keywords

Drug delivery system; Intravitreal injection; Nanoparticles; Nanotechnology; Posterior segment eye disease

Indexed keywords

CYCLODEXTRIN; LIPOSOME; NANOCARRIER; NANOPARTICLE; NANOSPHERE;

BLOOD RETINA BARRIER; DRUG PENETRATION; GEL; GENE THERAPY; HUMAN; NANOEMULSION; NANOTECHNOLOGY; NONHUMAN; RETINA DISEASE; REVIEW; SUSPENSION;

EID: 84912530140     PISSN: 13194534     EISSN: 25426680     Source Type: Journal    
DOI: 10.1016/j.sjopt.2014.02.009     Document Type: Review

References (79)

1. Bourges J.L., Bloquel C., Thomas A., Froussart F., Bochot A., Azan F., et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006, 58:1182-1202.
2. Gaudana R., Ananthula H.K., Parenky A., Mitra A.K. Ocular drug delivery. AAPS J 2010, 12(3):348-360.
3. Liu S., Jones L., Gu F.X. Nanomaterials for ocular drug delivery. Macromol Biosci. 2012, 12(5):608-620.
4. Lang J.C., Roehrs R.E., Jani R. Ophthalmic preparations. Remington, the science and practice of pharmacy 2006, 850-870. Lippincott Williams & Williams, Philadelphia. 21st ed. P. Beringer, P.K. Gupta (Eds.).
5. Rache J.M., Merodio M., Arnedo A., et al. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini-Rev Med Chem 2005, 5:293-305.
6. DeKozak Y., Andrieux K., Villarroya H., et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 2004, 34:3702-3712.
7. Yasukawa T., Ogura Y., Tabata Y., Kimura H., Wiedemann P., Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 2004, 23(3):253-281.
8. Prausnitz M.R., Noonan J.S. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 1998, 87:1479-1487.
9. Hämäläinen K.M., Kontturi K., Auriola S., et al. Estimation of pore size and pore density of biomembranes from permeability measurements of polyethylene glycols using an effusion-like approach. J Contro l Rel 1997, 49:97-104.
10. Mannermaa E., Vellonen K.-S., Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006, 58:1136-1163.
11. Klyce S.D., Crosson C.E. Transport processes across the rabbit corneal epithelium: a review. Curr Eye Res 1985, 4(4):323-331.
12. Barar J., Javadzadeh A.R., Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin Drug Deliv 2008, 5(5):567-581.
13. Gaudana R., Jwala J., Boddu S.H., Mitra A.K. Recent perspectives in ocular drug delivery. Pharm Res 2009, 26(5):1197-1216.
14. Ghate D., E delhauser H.F. Ocular drug delivery. Expert Opin Drug Deliv 2006, 3:275-287.
15. Hämäläinen K.M., Kananen K., Auriola S., et al. Characterization of paracellular and aqueous penetration routes in cornea conjunctiva, and sclera. Invest Ophthalmol Vis Sci 1997, 38:627-633.
16. Holland G.N., Sakamoto M.J., Hardy D., Sidikaro Y., Kreiger A.E., Frenkel L.M. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl guanine. Arch Ophthalmol 1986, 104(12):1794-1800.
17. MacCumber M.W., Sadeghi S., Cohen J.A., Deutsch T.A. Suture loop to aid in ganciclovir implant removal. Arch Ophthalmol 1999, 117(9):1250-1254.
18. Yang C.S., Khawly J.A., Hainsworth D.P., Chen S.N., Ashton P., Guo H., et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil co-drug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998, 116:69-77.
19. Akula S.K., Peyman G.A., Rahimy M.H., Hyslop N.E., Janney A., Ashton P. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol 1999, 78:667-680.
20. Smith T.J., Pearson P.A., Blanford D.L., Brown J.D., Goins K.A. Intravitreal sustained-release ganciclovir. Arch Ophthalmol 1992, 110:255-258.
21. Ussery F.M., Gibson S.R., Conklin R.H., Piot D.F., Stool E.W., Conklin A.J. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988, 95(5):640-648.
22. Stefánsson E., Loftsson T. Cyclodextrins in ocular drug delivery. J Drug Deliv Sci Technol 2007, 17:3-9.
23. Ebrahim S., Peyman G.A., Lee P.J. Applications of liposomes in Ophthalmology. Surv Ophthalmol 2005, 50:167-182.
24. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303(5665):1818-1822.
25. Oku N. Anticancer therapy using glucuronate modified long-circulating liposomes. Adv Drug Deliv Rev 1999, 40(1-2):63-73.
26. VanRooijen N., VanNieuwmegen R. Liposome in Immunology: Multilamellar Phosphatidyl choline Liposomes as a simple biodegradable and harmless adjuvant without any immunogenic activity of its own. Immunol Commun 1980, 9(3):243-256.
27. Bochot A., Fattal E., Boutet V., et al. Intravitreal delivery of oligonucleotides bysterically stabilized liposomes. Invert Ophthalmol Vis Sci 2002, 43:253-259.
28. Deshpande S., Patil S., Kuchibhatla S.V., Seal S. Size dependency variation in lattice parameter and valency states in nanocrystalline cerium oxide. Appl Phys Lett 2005, 87:133113.
29. 2-x nanocrystalline particles. Appl Surface Sci 1999, 152:53-56.
30. Zhou X., Wong L.L., Karakoti A.S., Seal S., McGinnis J.F. Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the vldlr knockout mouse. PLoS One 2011, 6:e16733.
31. Fattal E., Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers, siRNA. Adv Drug Deliv Rev 2006, 58:1203-1223.
32. Díaz-Llopis M., Martos M.J., España E., et al. Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Experimental toxicity and pharmacokinetics, and clinical trial. Doc Ophthalmol 1992, 82(4):297-305.
33. Akula S.K., Ma P.E., Peyman G.A., et al. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol 1994, 78(9):677-680.
34. Zeng S., Hu C., Wei H., et al. Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model. Ophthalmology 1993, 100(11):1640-1644.
35. Cannon J.P., Fiscella R., Pattharachayakul S., et al. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci 2003, 44(5):2112-2117.
36. Bochot A., Couvreur P., Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res 2000, 19(2):131-147.
37. Abrishami M., Zarei-Ghanavati S., Soroush D., Rouhbakhsh M., Jaafari M.R., Malaekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina 2009, 29(5):699-703.
38. Alghadyan A.A., Peyman G.A., Khoobehi B., Liu K.R. Liposome-bound cyclosporine: retinal toxicity after intravitreal injection. Int Ophthalmol 1988, 12(2):105-107.
39. Assil K.K., Hartzer M., Weinreb R.N., Nehorayan M., Ward T., Blumenkranz M. Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes. Invest Ophthalmol Vis Sci 1991, 32(11):2891-2897.
40. Gariano R.F., Assil K.K., Wiley C.A., Munguia D., Weinreb R.N., Freeman W.R. Retinal toxicity of the antimetabolite 5-fluorouridine 5'-monophosphate administered intravitreally using multivesicular liposomes. Retina 1994, 14(1):75-80.
41. Gupta S.K., Velpandian T., Dhingra N., Jaiswal J. Intravitreal pharma cokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J Ocul Pharmacol Ther 2000, 16(6):511-518.
42. Zhang R., He R., Qian J., Guo J., Xue K., Yuan Y.F. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci 2010, 51(7):3575-3582.
43. Kim E.K., Kim H.B. Pharmacokinetics of intravitreally injected liposome-encapsulated tobramycin in normal rabbits. Yonsei Med J 1990, 31(4):308-314.
44. Lajavardi L., Bochot A., Camelo S., et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci 2007, 48(7):3230-3238.
45. Honda M., Asai T., Umemoto T., Araki Y., Oku N., Tanaka M. Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416. Arch Ophthalmol 2011, 129(3):317-321.
46. Kawakami S., Yamamura K., Mukai T., et al. Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. J Pharm Pharmacol 2001, 53(8):1157-1161.
47. Wiechens B., Neumann D., Grammer J.B., Pleyer U., Hedderich J., Duncker G.I. Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes. Int Ophthalmol 1998-1999, 22(3):133-143.
48. Thrimawithana T.R., Young S., Bunt C.R., Green C., Alany R.G. Drug delivery to the posterior segment of the eye. Drug Discov Today 2011, 16(5-6):270-277.
49. Giordano G.G., Chevez-Barrios P., Refojo M.F., Garcia C.A. Biodegradation and tissue reaction to intravitreous biodegradable poly(d, l-lactic-co-glycolic)acid microspheres. Curr Eye Res 1995, 14(9):761-768.
50. Moritera T., Ogura Y., Honda Y., Wada R., Hyon S.H., Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci 1991, 32(6):1785-1790.
51. Sakurai E., Ozeki H., Kunou N., Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res 2001, 33(1):31-36.
52. Vandamme T.F. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res 2002, 21(1):15-34.
53. Fialho S.L., da Silva-Cunha A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Exp Ophthalmol 2004, 32(6):626-632.
54. Leary J.F. Nanotechnology: what is it and why is small so big?. Can J Ophthalmol 2010, 45:449-456.
55. Silva G.A., Czeisler C., Niece K.L., et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 2004, 303:1352-1355.
56. Silva G.A. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci 2006, 7:65-74.
57. Patolsky F., Timko B.P., Yu G., et al. Detection, stimulation, and inhibition of neuronal signals with high-density nanowire transistor arrays. Science 2006, 313:1100-1104.
58. Kotov N.A., Winter J.O., Clements I.P., et al. Nanomaterials for neural interfaces. Adv Mater 2009, 21:3970-4004.
59. Gal A., Li Y., Thompson D.A., et al. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet 2000, 26:270-271.
60. Charbel Issa P., Bolz H.J., Ebermann I., Domeier E., Holz F.G., Scholl H.P. Characterisation of severe rod-cone dystrophy in a consanguineous family with a splice site mutation in the MERTK gene. Br J Ophthalmol 2009, 93:920-925.
61. Mackay D.S., Henderson R.H., Sergouniotis P.I., et al. Novel mutations in MERTK associated with childhood onset rod-cone dystrophy. Mol Vis 2010, 16:369-377.
62. Vollrath D., Feng W., Duncan J.L., et al. Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci 2001, 98:12584-12589.
63. Sakai T., Kuno N., Takamatsu F., et al. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in royal college of surgeons rats. Invest Ophthalmol Vis Sci 2007, 48:3381-3387.
64. Dugan L.L., Lovett E.G., Quick K.L., Lotharius J., Lin T.T., O'Malley K.L. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 2001, 7:243-246.
65. Shen J.K., Dong A., Hackett S.F., Bell W.R., Green W.R., Campochiaro P.A. Oxidative damage in age-related macular degeneration. Histol Histopathol 2007, 22:1301-1308.
66. Komeima K., Rogers B.S., Campochiaro P.A. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol 2007, 213:809-815.
67. Papp A., Nemeth I., Karg E., Papp E. Glutathione status in retinopathy of prematurity. Free Radic Biol Med 1999, 27:738-743.
68. Mo Y., Barnett M.E., Takemoto D., Davidson H., Kompella U.B. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis 2007, 13:746-757.
69. Prow T., Grebe R., Merges C., et al. Nanoparticle tethered antioxidant response element as a biosensor for oxygen induced toxicity in retinal endothelial cells. Mol Vis 2006, 12:616-625.
70. Cai X., Conley S., Naash M. Nanoparticle applications in ocular gene therapy. Vis Res 2008, 48:319-324.
71. Farjo R., Skaggs J., Quiambao A.B., Cooper M.J., Naash M.I. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One 2006, 1:e38.
72. Cai X., Nash Z., Conley S.M., Fliesler S.J., Cooper M.J., Naash M.I. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One 2009, 4:e5290.
73. Cai X., Conley S.M., Nash Z., Fliesler S.J., Cooper M.J., Naash M.I. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J 2010, 24:1178-1191.
74. Streilein J.W. Limitations in the study of immune privilege in the subretinal space of the rodent. Invest Ophthalmol Vis Sci 1999, 40:3069.
75. Petrs-Silva H., Dinculescu A., Li Q., et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009, 17:463-471.
76. Surace E.M., Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vis Res 2008, 48:353-359.
77. Maguire A.M., Simonelli F., Pierce E.A., et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008, 358:2240-2248.
78. Hauswirth W.W., Aleman T.S., Kaushal S., et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adenoassociated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008, 19:979-990.
79. Bainbridge J.W., Smith A.J., Barker S.S., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358:2231-2239.